EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin

Mihir Parikh, Jiajie Pu, Junwei Shen, Caroline K Kramer, Bernard Zinman, Jacqueline L Beaudry, Ravi Retnakaran iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Mihir Parikh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada M5S 1A8. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide 1, Insulin Glargine. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Diabetes Canada, CIHR, University of Toronto Faculty of Medicine, BBDC and Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Prolonged exposure to hormonal therapy can affect endogenous hormone secretion. In type 2 diabetes (T2DM), glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being administered in combination with therapies targeting additional hormones (including glucose-dependent insulinotropic polypeptide [GIP], glucagon, and insulin). However, little is known on how they affect endogenous GLP-1 secretion.

Objective

We sought to evaluate the effect of exenatide b.i.d on endogenous secretion of GLP-1, GIP, and glucagon in patients treated concurrently with basal insulin. Design/Setting/Patients In this trial, adults with T2DM were randomized to 8-week treatment with basal insulin glargine (Glar; n = 30), glargine plus thrice-daily lispro (Glar/Lispro; n = 32), or glargine plus twice-daily exenatide (Glar/Exe; n = 31). Outcome Endogenous secretion of glucagon, GIP and GLP-1 was assessed on 2-hour oral glucose tolerance test (OGTT) at baseline and after stopping therapy at 8 weeks, during which their circulating concentrations were measured every 30 minutes.

Results

There were no differences between groups in response profiles of glucagon and GIP. While there were no differences in fasting GLP-1, Glar/Exe induced higher GLP-1 concentrations than the other treatments at 30 and 60 minutes post-challenge at 8 weeks (both P < .05). On the 8-week OGTT, baseline-adjusted GLP-1 was the highest in Glar/Exe at each of 30 minutes (P = .037), 60 minutes (P = .007), and 90 minutes (P = .039). Unlike the respective between-group comparisons of baseline-adjusted area-under-the-curve (AUC) for glucagon and GIP (both P = NS), baseline-adjusted AUCGLP-1 at 8 weeks was the highest in Glar/Exe (P = .037).

Conclusion

When combined with basal insulin therapy, exenatide induces an enhanced post-challenge endogenous GLP-1 secretory response following its cessation, with no differential effect on glucagon and GIP secretion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide 1Insulin GlarginePeptidesInsulinVenomsHumansExenatideMaleFemaleMiddle AgedGlucagonGastric Inhibitory PolypeptideAgedBlood GlucoseGlucose Tolerance TestAdultDrug Therapy, Combination

Stichwörter der Autor:innen

GIPGLP-1GLP-1 receptor agonistexenatideglucagonhormone

Substanzen

ExenatideHypoglycemic AgentsGlucagon-Like Peptide 1GlucagonGastric Inhibitory PolypeptideInsulin GlarginePeptidesInsulinBlood GlucoseVenoms

Autor:innen und Institutionen

  • Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada M5S 1A8.
  • Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada M5T 3L9.
  • Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Canada M5S 1A8.
  • Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada M5G 1X5.

ORCID-Profile: Ravi Retnakaran

Förderung

  • Diabetes Canada
  • CIHR
  • University of Toronto Faculty of Medicine, BBDC and Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research
  • Canadian Institutes of Health Research

Zitieren

APA

Parikh, M., Pu, J., Shen, J., Kramer, C. K., Zinman, B., Beaudry, J. L., & Retnakaran, R. (2026). Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag033

Vancouver

Parikh M, Pu J, Shen J, Kramer CK, Zinman B, Beaudry JL, et al. Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag033

BibTeX
@article{Parikh2026,
  author = {Parikh, Mihir and Pu, Jiajie and Shen, Junwei and Kramer, Caroline K and Zinman, Bernard and Beaudry, Jacqueline L and Retnakaran, Ravi},
  title = {Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag033}
}
Kostenlos starten →